611 W. Union Street
Benson, AZ 85602
(520) 586-0800

LaFrontera
member support line
1-520-279-5737
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Medical Disorders
Resources
Basic InformationLookupsLatest News
Strokes Are Deadlier When They Hit COVID-19 PatientsAHA News: How to Accurately Measure Blood Pressure at HomeU.S. Earmarks $1.2 Billion for New Vaccine Deal as Coronavirus Deaths Near 95,000During the Pandemic, How Safe Is the Great American Summer Vacation?COVID-19 Damages Lungs Differently From the Flu: StudyMore Evidence Hydroxychloroquine Won't Help, May Harm COVID-19 PatientsYour Sleep Habits May Worsen Your AsthmaExtra Pounds Could Bring More Painful JointsCOVID Can Complicate Pregnancy, Especially If Mom Is ObeseWHO Predicts COVID-19 Will Take Heavy Toll in AfricaCombining Remdesivir With Other Meds Could Boost COVID-Fighting PowerMultiple Sclerosis Ups Odds for Heart Trouble, StrokeAHA News: Not Wanting to Burden Busy Hospitals, She Disregarded Heart Attack SignsExperimental Vaccines Shield Monkeys From CoronavirusHeart Attack Cases at ERs Fall by Half – Are COVID Fears to Blame?Asthma Ups Ventilator Needs of Younger Adults With COVID-19: Study1 in 5 Hospitalized NYC COVID-19 Patients Needed ICU CareObesity Ups Odds for Dangerous Lung Clots in COVID-19 PatientsDoes 6 Feet Provide Enough COVID Protection?COVID-19 Antibodies May Tame Inflammatory Condition in Kids: StudyAs Americans Return to Work, How Will COVID Change the Workplace?COVID and Hypochondria: Online Therapy May Help Ease FearsAHA News: Is High Blood Pressure Inevitable?People Mount Strong Immune Responses to Coronavirus, Boding Well for a VaccineProms Gone, Graduations Online: Pandemic Cancels Kids' Rites of PassageDon't Delay If Cancer Symptoms Appear – Call Your DoctorPulmonary Rehab Can Help People With COPD, So Why Do So Few Get It?COVID-19 Will Delay 28 Million Elective Surgeries Worldwide: StudyMost U.S. States Reopening as Coronavirus Cases DeclineRate of New U.S. Coronavirus Cases Is DecliningCould Certain Chemicals Trigger Celiac Disease?Poor Americans Likely to Miss Preventive Heart Screenings: Study2 More Studies Throw Cold Water on Hydroxychloroquine as COVID-19 TreatmentNewborn May Have Contracted Coronavirus in the Womb: ReportCould Interferon Drugs Help Fight COVID-19?COVID-19 Is More Severe in SmokersCDC Issues Guidelines for Reopening AmericaToo Many Sugary Sodas Might Harm Your KidneysBy the Numbers, COVID-19 Was Never 'Like the Flu'Compression Stockings May Not Be Needed After Surgeries, Study FindsMore COVID Casualties: Stroke Victims Who Put Off TreatmentSmell Diminishes by Day 3 of COVID-19, Study SaysStudies Show COVID-19 Can Infect and Harm Digestive OrgansSpeech Alone May Spread COVID-19, Study ShowsCOVID-19 Facts or Fiction: 1 in 4 YouTube Videos Misleads ViewersItalian Doctors Detail Cases of Inflammatory Condition in Kids With COVID-19Most Workers Report for Duty With Flu-Like Symptoms, Global Survey ShowsPandemic Is Putting Cutting-Edge Cancer Research on Hold: SurveyNervous About Returning to Work? Take Precautions Against CoronavirusCould Survivors' Blood Help Patients Battling COVID-19? Trials May Tell
Questions and AnswersLinksBook Reviews
Related Topics

Cancer
Men's Health
Women's Health

Zerbaxa Approved for Hospital-Acquired Bacterial Pneumonia


HealthDay News
Updated: Jun 11th 2019

new article illustration

TUESDAY, June 11, 2019 (HealthDay News) -- Zerbaxa (ceftolozane and tazobactam) has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients aged 18 years and older, the U.S. Food and Drug Administration announced yesterday.

In 2014, the FDA first approved Zerbaxa for treating complicated intra-abdominal infections and urinary tract infections. According to the manufacturer's prescribing information, Zerbaxa is administered in a recommended dosage regimen of a 1.5-g injection every eight hours by intravenous infusion for one hour. Treatment duration should be based on the infection site and severity and the patient's progress.

In a multinational, double-blind study of 726 patients hospitalized with HABP/VABP who were injected with Zerbaxa or another antibacterial drug, researchers found similar mortality and cure rates between the two drugs. The most commonly reported adverse reactions among patients treated with Zerbaxa included elevated liver enzyme levels, renal impairment or failure, and diarrhea.

The FDA notes that Zerbaxa should not be used in patients known to have serious hypersensitivity to the drug's components or to piperacillin/tazobactam or other antibacterial drugs in the beta lactam class.

Approval of Zerbaxa for this new indication was granted to Merck and Co.

More Information